Accelerated evolution of resistance in multidrug environments
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
The emergence of resistance during multidrug chemotherapy impedes the treatment of many human diseases, including malaria, TB, HIV, and cancer. Although certain combination therapies have long been known to be more effective in curing patients than single drugs, the impact of such treatments on the evolution of drug resistance is unclear. In particular, very little is known about how the evolution of resistance is affected by the nature of the interactions—synergy or antagonism—between drugs. Here we directly measure the effect of various inhibitory and subinhibitory drug combinations on the rate of adaptation. We develop an automated assay for monitoring the parallel evolution of hundreds of Escherchia coli populations in a two-dimensional grid of drug gradients over many generations. We find a correlation between synergy and the rate of adaptation, whereby evolution in more synergistic drug combinations, typically preferred in clinical settings, is faster than evolution in antagonistic combinations. We also find that resistance to some synergistic combinations evolves faster than resistance to individual drugs. The accelerated evolution may be due to a larger selective advantage for resistance mutations in synergistic treatments. We describe a simple geometric model in which mutations conferring resistance to one drug of a synergistic pair prevent not only the inhibitory effect of that drug but also its enhancing effect on the other drug. Future study of the profound impact that synergy and other drug-pair properties can have on the rate of adaptation may suggest new treatment strategies for combating the spread of antibiotic resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the interactions can be highly dosedependent”
Citations
Cites
Chopra, I., & Roberts, M. (2001) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.65.2.232-260.2001 · Cited by 4,517 · cited 2×
“To experimentally explore the relation between drug interaction and the rate of adaptation, we compared a drug pair that exhibits strong antagonism [doxycycline (DOX), a tetracycline antibiotic, and ciprofloxacin (CIP), a fluoroquinolone] to another pair showing strong synergy [DOX and a macrolide antibiotic, erythrom…”
BackgroundAntibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Antibiotics in Laboratory Medicine.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,779
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Darwinian Evolution Can Follow Only Very Few Mutational Paths to Fitter Proteins
Weinreich, D. M., Delaney, N. F., DePristo, M. A., & Hartl, D. L. (2006) · Science · doi:10.1126/science.1123539 · Cited by 1,415
Self-citationBerenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Evolution Experiments with Microorganisms: The Dynamics and Genetic Bases of Adaptation
Elena, S. F., & Lenski, R. E. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1088 · Cited by 1,386
Antibiotics: Actions, Origins, Resistance
Walsh, C. T. (2003) · Medical Entomology and Zoology · Cited by 675
Antibiotics: Actions, Origins, Resistance
Walsh, C. (2003) · Wiley eBooks · doi:10.1128/9781555817886 · Cited by 633
Lack of development of new antimicrobial drugs: a potential serious threat to public health
Norrby, S. R., Nord, C. E., & Finch, R. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)01283-1 · Cited by 491
Antibiotic interactions that select against resistance
Chait, R., Craney, A., & Kishony, R. (2007) · Nature · doi:10.1038/nature05685 · Cited by 439
Self-citationThe mutant selection window and antimicrobial resistance
Drlica, K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg269 · Cited by 437
Bacterial resistance to aminoglycoside antibiotics
Davies, J., & Wright, G. D. (1997) · Trends in Microbiology · doi:10.1016/s0966-842x(97)01033-0 · Cited by 403
Functional classification of drugs by properties of their pairwise interactions
Yeh, P., Tschumi, A. I., & Kishony, R. (2006) · Nature Genetics · doi:10.1038/ng1755 · Cited by 350
Self-citationAn Equivalence Principle for the Incorporation of Favorable Mutations in Asexual Populations
Hegreness, M., Shoresh, N., Hartl, D., & Kishony, R. (2006) · Science · doi:10.1126/science.1122469 · Cited by 250
Self-citationThe population dynamics of antimicrobial chemotherapy
Lipsitch, M., & Levin, B. R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.363 · Cited by 237
Antimicrobial resistance: a global response.
Smith, R., & Coast, J. (2002) · Europe PMC (PubMed Central) · Cited by 222
Bliziotis, I. A., Samonis, G., Vardakas, K. Z., Chrysanthopoulou, S., & Falagas, M. E. (2005) · Clinical Infectious Diseases · doi:10.1086/430912 · Cited by 219
Clinical Significance of In Vitro Synergism Between Antibiotics in Gram-Negative Infections
Klastersky, J., Cappel, R., & Daneau, D. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.6.470 · Cited by 186
Exposing the fitness contribution of duplicated genes
DeLuna, A., Vetsigian, K., Shoresh, N., Hegreness, M., Colón-González, M., Chao, S., & Kishony, R. (2008) · Nature Genetics · doi:10.1038/ng.123 · Cited by 182
Self-citationChemotherapy of Pulmonary Tuberculosis in Young Adults
Daniels, M., & Hill, A. B. (1952) · BMJ · doi:10.1136/bmj.1.4769.1162 · Cited by 142
Genetic Studies on Microbial Cross Resistance to Toxic Agents
Szybalski, W. (1954) · Applied Microbiology · doi:10.1128/am.2.2.57-63.1954 · Cited by 137
Genetic Studies on Microbial Cross Resistance to Toxic Agents
Szybalski, W. (1954) · Applied Microbiology · doi:10.1128/aem.2.2.57-63.1954 · Cited by 117
Rodríguez-Martínez, J. M., Velasco, C., García, I., Cano, M. E., Martínez-Martínez, L., & Pascual, A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01444-06 · Cited by 76
Synergy with double and triple antibiotic combinations compared
Berenbaum, M. C., Yu, V. L., & Felegie, T. P. (1983) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/12.6.555 · Cited by 36
THE ROLE OF BACTERIAL RESISTANCE IN ANTIBIOTIC SYNERGISM AND ANTAGONISM
Klein, M., & Schorr, S. E. (1953) · Journal of Bacteriology · doi:10.1128/jb.65.4.454-465.1953 · Cited by 31
An unusual interaction between the target of nalidixic acid and novobiocin
Chao, L. (1978) · Nature · doi:10.1038/271385a0 · Cited by 28
Gunnison, J. B., Shevky, M. C., Bruff, J. A., Coleman, V. R., & Jawetz, E. (1953) · Journal of Bacteriology · doi:10.1128/jb.66.2.150-158.1953 · Cited by 18
INFECTIOUS DISEASES: PROBLEMS OF ANTIMICROBIAL THERAPY
Jawetz, E. (1954) · Annual Review of Medicine · doi:10.1146/annurev.me.05.020154.000245 · Cited by 17
Should Antibiotic Combinations Be Used to Treat Ventilator-Associated Pneumonia?
Eggimann, P., & Revelly, J. (2006) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2006-933675 · Cited by 17
Daschner, F. D. (1976) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.10.5.802 · Cited by 14
The Problem of Bacterial Resistance in Antimicrobial Therapy of Tuberculosis
Sweany, H. C., Dunbar, F. P., & WOOD, E. (1955) · Diseases of the Chest · doi:10.1378/chest.28.3.260 · Cited by 4
Research works printed but not linked: 1
- 10.1016/s1473-3099(05)70086-4 · doi:10.1016/s1473-3099(05)70086-4 · Paper page
Cited by
A brief history of the antibiotic era: lessons learned and challenges for the future
Aminov, R. I. (2010) · Frontiers in Microbiology · doi:10.3389/fmicb.2010.00134 · Cited by 1,628
Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects
Uddin, T. M., Chakraborty, A. J., Khusro, A., Zidan, B. R. M., Mitra, S., Emran, T. B., Dhama, K., Ripon, M. K. H., Gajdács, M., Sahibzada, M. U. K., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.10.020 · Cited by 1,311
Sublethal Antibiotic Treatment Leads to Multidrug Resistance via Radical-Induced Mutagenesis
Kohanski, M. A., DePristo, M. A., & Collins, J. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.003 · Cited by 985
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
Drug combinations: a strategy to extend the life of antibiotics in the 21st century
Tyers, M., & Wright, G. D. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0141-x · Cited by 820
Metadata
- Authors
- Hegreness, M., Shoresh, N., Damian, D., Hartl, D., & Kishony, R.
- Affiliations
- Harvard University (US)
- *Department of Systems Biology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115;
- Vertex Pharmaceuticals (United States) (US)
- Department of Organismic and Evolutionary Biology and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-09-16
- Volume
- 105
- Issue
- 37
- Pages
- 13977-13981
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2544564
- OpenAlex
- W2080777238
- Cited by
- 300
- References
- 33
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 23 · 2023: 26 · 2022: 12 · 2021: 21 · 2020: 18 · 2019: 20 · 2018: 12 · 2017: 28 · 2016: 18 · 2015: 21 · 2014: 18 · 2013: 21 · 2012: 7
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of General Medical Sciences (R01GM081617)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Evolution and Genetic Dynamics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- drug resistance evolution, multidrug chemotherapy, drug synergy, drug antagonism, combination therapy, rate of adaptation, Escherichia coli, parallel evolution, antibiotic resistance, resistance mutations
- MeSH terms
- Adaptation, Biological, Biological Evolution, Drug Resistance, Multiple
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.